Simon Crawford Consultant gynaecologist (chair UHS

Transcription

1 Minutes WESSEX CANCER STRATEGIC CLINICAL NETWORK (SCN) SITE SPECIFIC CHAIRS MEETING 14 th May :00 to 12:00pm in Meeting Room 2, NHS England (Wessex), Oakley Road Present: Name Role Organisation Matthew Hayes Clinical Director, Cancer SCN, Chair NHS England Stephen Andrews Consultant Urologist (chair Dorset urology Dorchester Hospital group) Simon Crawford Consultant gynaecologist (chair UHS Hampshire/IOW gynae group) Jonathan Cullis Consultant Haematologist, Chemo lead Salisbury Hospital Chrissy Day Cancer Manager UHS Paul Fenton Consultant Clinical Oncologist (co-chair UHS AOS group Wessex) Kevin Harris Consultant Surgeon (chair HHFT Hampshire/IOW breast group) Andrea Hollings Dorset SSG administrator Dorchester Hospital Matthew Jenner Consultant Haematologist (chair Hampshire/IOW haematology group) UHS Peter Nieuwets Specialised commissioning NHS England Alan Parker Carer Rep for Peter Pitcher (palliative care group) Darren Maytham Cancer Service Manager UHS Sally Rickard SCN Manager NHS England Teresa Warr Specialised commissioning NHS England Apologies Name Role Organisation Caroline Archer Oncology consultant Portsmouth Hospitals Suhail Baluch Oncology consultant Portsmouth Hospitals Vanessa Basketter Clinical Nurse Specialist Portsmouth Hospitals Lesley Bishop Cancer Group Chair Portsmouth Hospitals Susan Burroughs Cancer Group Chair Salisbury Hospital Tom Cecil Cancer Group Chair HHFT Arnie Drury Radiologist, CD RBM, Cancer Lead RBH Imaging Danny Dubois Cancer Group Chair Portsmouth Hospitals Abigail Evans Consultant Surgeon Poole Dr Rachel Hall Consultant Haematologist RBH Catriona Henderson Lead Skin Cancer UHS Janet Holder Lead Skin Cancer HHFT Andrew Jackson Radiotherapy network chair UHS Stephen Keohane Cancer Group Chair Portsmouth Hospitals Emma King Head & Neck Chair, Dorset Poole Diane Laws Consultant Physician RBCH Elaine Lennan Consultant Nurse Specialist UHS Caroline Morgan Consultant Dermatologist Poole Gary Nicolin Consultant Paediatric Oncologist UHS Richard Osborne Lead Cancer Clinician Poole Nimesh Patel Head and Neck Chair, Hampshire/IOW UHS Peter Pitcher Cancer Group Chair Oak Haven Hospice Lynne Richley Specialised commissioning NHS England Kim Sanderson Radiotherapy Services Manager Portsmouth Hospitals Linda Sayburn Care Group Manager UHS

2 Peter Simmonds Consultant Medical Oncologist UHS Tony Skene NSSG Chair Thyroid Endocrine (Sarcoma) Bournemouth James Smart Cancer Group Chair UHS Brian Stedman Cancer Group Chair UHS Ann Suovuori Oncology consultant Portsmouth Hospitals Item Subject Action 1.0 Matthew Hayes, Clinical Director, Cancer Strategic Clinical Network Welcome and Introduction Matthew Hayes welcomed those present and acknowledged the spread of expertise in the region. Following the closure of the old cancer networks, Site Specific Groups (SSGs) were left unsupported. The new Wessex Strategic Clinical Network for Cancer is keen to enable to continued and enhanced function of the SSGs, but taking the opportunity to refocus the agenda. Introduction. Key questions for discussion: Are the SSGs provider led and supported? Should SSGs function at regional (Wessex wide) level, or remain county autonomous? Should SSGs look to increase functional integration across health and social care? Discussion points: Dorset - there are currently active groups in Breast, Upper GI, Endocrine, Thyroid, Skin, Urology, CUP, Colorectal, Gynaecology, Palliative care, Lung and Wessex end of life network. All will have met by the end of June (colorectal TBC) Chemotherapy SSG - at present there is no group active in Dorset, Tom Geldart was the previous chair. All agreed there were benefits in establishing a Wessex wide chemotherapy group, noting the difference in Dorset and Central South Coast E Prescribing systems. The previous Central South Coast Chemo group are meeting at the end of May and can discuss views on creating a regional wide versus autonomous group. Elaine Lennan is part of the Chemo SSG and also the Wessex representative on the national Clinical Reference Group (CRG) for chemotherapy. CRGs are currently finalising service level strategies to be published during the summer. This will set the service specifications at a national level. Haematology first meeting of the new Wessex wide SSG in September. AOS Wessex wide group active and functioning successfully with full engagement from a wide range of trusts and professionals. Hampshire/IOW Chairs are nominated for most of the SSGs. Previous constitutional documents have been recirculated for review. Meetings are now used to drive the clinical agenda. Each SSG will aim to have met by the end of July. Maria Dias Haigh to be replaced by Sophia Armitage at UHS as admin lead for SSGs. Sophia.armitage@uhs.nhs.uk Brain/CNS and others challenges in engagement for brain, CNS, spinal and pancreatic SSGs as all services are provided

3 by UHS. Head and neck services are being centralised, there is less incentive for other trusts to join an SSG. Discussion summary: Most SSGs are active, provider led and supported. Confirmation of the requirement under Peer Review for providers to support SSG attendance is welcome. For some SSGs a Wessex wide model is clearly beneficial, however not all. Agreed the need for a regional group would be discussed within each SSG. SSGs and Commissioners should interface. The SSG can be a place for commissioning issues to be bought and all would welcome attendance from CCG representatives. CCG commissioners expressed a similar wish at the Cancer SCN meeting on 13 th May. functional integration across health and social care to be discussed as a future agenda item. Actions: AH & SA to follow up with medical oncology teams in Dorset views on establishing a Wessex wide Chemotherapy SSG. 2.0 Feedback from SSG chairs present SR AH/SA Simon Crawford (Gynaecology) Next SSG meeting planned for the autumn joint with Dorset (Richard Osborne to attend for Dorset) Southampton has met with all DGH providers successfully Historically the SSG had low engagement, SW keen to collaborate with the 3 centres for gynaecology, UHS, Portsmouth and Poole. Alan Parker (a member - Dorset specialised palliative care) Ross Pugh is the chair of the Dorset SSG. There is large provider representation. There is likely to continue to be two separate SSGs for Dorset and Hampshire / IoW. Kevin Harris (Breast) Old network was very successful. The group last met in September Next meeting is 18 th July with new administrative support. Matthew Jenner (Haematology) There is an issue of concern with the haematology group in retaining valued lay representation on the group. Funding from the previous Cancer Network is no longer available. Action MH/SR. Paul Fenton (Acute Oncology Service (AOS) A successful new Wessex wide network has been established. Facing challenges such as a network wide audit without additional resource. Audit is required for Peer Review, Clinical Safety and care. The SSG is a mechanism for influencing national strategies and has identified the importance of a CRG representative on the membership (Elaine Lennan) Stephen Andrews (Urology) Meeting scheduled for 19 th June to reestablish the SSG. A Wessex wide meeting is to be held in September, SA to attend. The network is currently established in Dorset, and open to a Wessex wide group.

4 Primary Care Engagement Michelle Chesters SSG discussion historically focused too much on secondary care aspects of patient pathways.. Primary care presence at the meeting benefits communications, clinical scenarios etc. Macmillan GPs can relay SSG updates in ongoing GP Practice visits. Each Macmillan GP has a portfolio of interest. Actions: MH/SR to investigate sources of funding to enable lay representatives to continue on SSGs. SCN to link Macmillan GPs to attend SSGs across Wessex SCN to link CCG cancer leads to SSGs. 3.0 Teresa Warr Specialised Commissioning MH/SR Discussion: There are a total of 76 Clinical Reference Groups (CRGs) developing national service specifications. Was 75, Lung has now been added. If a provider is not compliant with the national specification derogation is a means through which an action plan is developed for the provider to become compliant. There is an issue in that there is only self-assessment of compliance; gaps are highlighted between assessment and Peer Review findings, e.g. E Prescribing derogation states fully operational system expected by July this will not be achievable with all protocols for all sites. Results of the first round of assessments have yet to be published, they were due in March this year. Peer Review is led by James Palmer, the Clinical Director of Specialised Services. February s risk based Peer Review reports highlighted two areas of concern: o o Brain CNS and Colorectal and anal cancers (the configuration does not meet the IOG) The colorectal SSG may be able to address the issues raised. Nick Beck to chair colorectal and anal cancer SSG and is aware of the issues raised. A detailed specification for skin services is available and should be reviewed by the Dorset and Hampshire Skin SSGs. NHS England is developing a 5 year strategy for cancer with service level links for each CRG. Actions: SR to recirculate TW presentation indicating which specification relates to which site and a list of references. SR to share list of SSG chairs with TW. 4.0 Peter Nieuwets IFR and CDF lead for South England CDF Presentation attached SR Discussion: National standards for IFR and CDF applications were published in January. Attached. IFR processes are becoming similar, reducing variation in funding decisions. Differences in decisions are now investigated Decisions are shared via the National Pharmacy Team.

5 The number of requests going to CDF has dropped as many screened out in advance of the panel meeting. Nationally the budget is at risk of significant overspend. 5.0 Matthew Hayes SSGs input into a cancer strategy for Wessex. The number of specialised centres to exist in England will be specified by NHS England in the summer. It is not yet clear if this number will be nearer to 15 or 30. At present there is also no clarity on definition of specialised. Implications for Wessex are different depending on the above definitions. This must be clear to inform development of a strategic vision for Cancer Services in Wessex. Peer review has highlighted the need for reconfiguration to deliver the national specification. Action: MH to contact Sean Duffy, National Clinical Director for Cancer, to request a steer to inform development of the Wessex region vision for future cancer services. 6.0 AOB MH Michelle Chesters highlighted that NICE are to review 2WW guidelines which is expected to lead to an increase in 2WW referrals from 1.2m currently to near 2m. Next meeting Tuesday 11th November :00 12:00 Meeting Room 2, NHS England (Wessex), Oakley Road, Southampton, Hampshire, SO16 4GX.